Prostate Cancer Dissemination Patterns

Primary Routes of Dissemination

Prostate cancer disseminates through three primary pathways: local extension through the prostatic capsule, lymphatic spread to regional and pelvic lymph nodes, and hematogenous spread predominantly to bone (occurring in 84% of metastatic cases) 1
The anatomic progression follows a predictable sequence through stages T1-T2 (confined to prostate), T3a (extracapsular extension), T3b (seminal vesicle invasion), and T4 (invasion of adjacent structures) 1
Approximately 70-85% of bladder urothelial carcinomas are non-muscle invasive at presentation, but invasion of the muscularis propria significantly increases risk for distant spread 2

Regional lymph nodes include pelvic nodes below the bifurcation of the common iliac arteries, with nodes ≥1.5 cm in short axis considered pathologically enlarged and measurable 3, 1
Pelvic nodal disease is classified as locoregional, while extrapelvic nodes (retroperitoneal, mediastinal, thoracic) are classified as metastatic (M1a disease) 3
Lymph nodes between 1.0-1.5 cm in short axis may be pathologic and can be considered non-measurable/non-target lesions 3

Hematogenous dissemination occurs predominantly after muscularis propria invasion, dramatically increasing the risk of distant metastases 1
The most common metastatic sites in order of frequency are: bone (84%), distant lymph nodes (10.6%), lung (9.1%), liver (10.2%), and other sites including adrenal glands and CNS 1, 4

The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) defines five distinct clinical subtypes that are prognostically important: locally recurrent/persistent disease, non-metastatic CRPC (nmCRPC), nodal disease only, bone disease, and visceral disease 3, 4, 5

PSA doubling time (PSADT) <6 months strongly suggests metastatic dissemination rather than local recurrence 6
The presence of visceral metastases indicates more aggressive disease and poorer prognosis compared to bone-only metastases 4
Patients with castration-resistant prostate cancer and bone metastases have a median survival of <2 years 4

Contrast-enhanced CT of chest, abdomen, and pelvis with ≤5 mm axial slices is recommended for all metastatic patients to assess nodal and visceral disease 5
Chest CT imaging is specifically recommended given the 7% prevalence of lung metastases in castration-resistant prostate cancer trials 5, 4
PSMA PET/CT has significantly superior accuracy compared to conventional imaging for detecting visceral metastases and is now the preferred imaging modality when available 6
Bone scintigraphy remains the standard for detecting skeletal metastases 4

Bone metastases may paradoxically appear worse on imaging despite effective treatment (flare phenomenon), leading to false interpretation of disease progression 4
CT, ultrasound, and MRI cannot always accurately predict the true depth of local invasion 6
A single negative imaging study does not definitively rule out metastatic disease when clinical suspicion is high 6

The obturator (medial external iliac) nodes are the most frequent site of prostate cancer nodal metastasis, followed sequentially by external iliac, internal iliac (hypogastric), presacral, and common iliac nodes. 7
Lymph nodes located beyond the regional pelvic groups (e.g., extrapelvic retro‑peritoneal, mediastinal, thoracic nodes) are classified as distant metastases (M1a) rather than regional disease. 8
Extrapelvic retroperitoneal nodes—including mediastinal and thoracic stations—are considered metastatic disease when involved. 8

Nodes with a short‑axis diameter ≥ 1.5 cm are deemed pathologically enlarged and measurable; nodes measuring 1.0–1.5 cm may be pathologic but are treated as non‑target lesions. 8
Pelvic nodal involvement is staged as locoregional (N‑stage), whereas involvement of any extrapelvic nodal basin is staged as distant metastasis (M1a). 8

A limited obturator‑only lymph node dissection fails to detect roughly 50 % of metastatic nodes, underscoring the need for a more comprehensive approach. 7
Extended pelvic lymph node dissection (ePLND) should systematically include the obturator, external iliac, internal iliac, presacral, and common iliac nodal groups to achieve adequate staging and therapeutic coverage. 7

Men with prostate‑specific antigen < 20 ng/mL, clinical stage < T2b, and Gleason score < 7 have a <10 % probability of lymph node metastasis and may be spared from invasive surgical staging. 7
Predictive nomograms can aid individualized risk estimation, but they may underestimate true risk because of stage migration over time. 9

Conventional cross‑sectional imaging (CT or MRI) identifies only about 40–50 % of nodal metastases, with particularly low sensitivity for microscopic disease. 7

All statements are supported by the cited references; strength of evidence was not explicitly reported in the source material.